Sotrovimab – UPSC Prelims

  • It has been developed by GlaxoSmithKline with US partner Vir Biotechnology Inc.
  • It is a monoclonal antibody drug that binds to the SARS-CoV-2 spike protein, thereby preventing the virus from attaching to and entering human cells.
  • It has been recommended for treating mild or moderate Covid-19 in patients who are at high risk of hospitalisation.
  • These include patients who are older, are immunocompromised, have underlying conditions like diabetes, hypertension and obesity and are unvaccinated.
Scroll to Top